Evidence map›Paper›PMID 28686664›Full record

Trial reportPloS one2017

Somatosensory function in patients with secondary adrenal insufficiency treated with two different doses of hydrocortisone-Results from a randomized controlled trial.

Jorien Werumeus Buning, Karl-Heinz Konopka, Pauline Brummelman, Janneke Koerts, Robin P F Dullaart, Gerrit van den Berg, Melanie M van der Klauw, Oliver Tucha, Bruce H R Wolffenbuttel, André P van Beek

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jorien Werumeus BuningDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0002-7918-4281
Karl-Heinz KonopkaDrug Discovery Science & Management-Europe, Astellas Pharma Europe B.V., Leiden, The Netherlands.
Pauline BrummelmanDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Janneke KoertsDepartment of Clinical and Developmental Neuropsychology, University of Groningen, Groningen, The Netherlands.
Robin P F DullaartDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Gerrit van den BergDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Melanie M van der KlauwDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Oliver TuchaDepartment of Clinical and Developmental Neuropsychology, University of Groningen, Groningen, The Netherlands.
Bruce H R WolffenbuttelDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
André P van BeekDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
University Medical Center Groningen · NLUniversity of Groningen · NLAstellas Pharma (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLow cortisol levels are associated with several functional pain syndromes. In patients with secondary adrenal insufficiency (SAI), the lack in endogenous cortisol production is substituted by the administration of oral hydrocortisone (HC). Our previous study showed that a lower dose of HC led to an increase in reported subjective pain symptoms. Whether different doses of HC substitution alter somatosensory functioning in SAI patients has not been established yet.

methodsIn this randomized double blind cross-over trial, forty-six patients with SAI participated. Patients randomly received either first a lower dose (0.2-0.3 mg HC/kg body weight/day) for 10 weeks followed by a higher dose (0.4-0.6 mg HC/kg body weight/day) for another 10 weeks, or vice versa. After each treatment period, blood samples were drawn and somatosensory functioning was assessed by determining the mechanical detection threshold (MDT), mechanical pain threshold (MPT), mechanical pain sensitivity (MPS) and the pain pressure threshold (PPT), according to the Quantitative Sensory Testing (QST) battery by the German Network on Neuropathic Pain.

resultsThe administration of the higher dose of HC resulted in significantly higher levels of cortisol (mean [SD] 748 [245] nmol/L) than the lower dose (537 [250] nmol/L, P<0.001). No differences were found in MDT, MPT, MPS and PPT z-scores between the two doses of HC. Furthermore, the number of patients showing sensory abnormalities did not differ between the two different doses.

conclusionsThe results suggest that the dose of HC has no impact on somatosensory functioning in response to mechanical stimuli in patients with SAI, despite previously found altered subjective pain reports.

Indexed as

Administration, OralAdrenal InsufficiencyAdultAnti-Inflammatory AgentsCross-Over StudiesDouble-Blind MethodDrug Administration ScheduleFemaleHormone Replacement TherapyHumansHydrocortisoneMaleMiddle AgedNeuralgiaPain MeasurementPain ThresholdAnti-Inflammatory AgentsHydrocortisone

Identifiers

PMID28686664
PMCPMC5501533
OpenAlexW2728428099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.